Mirna Therapeutics recently announced the appointment of Dr. Clay B Siegall as one of the outside directors of its board of directors. Mirna Therapeutics is a very famous biotechnology firm that was founded to develop and commercialize microRNA therapeutics.
Clay B. Siegall is one of the co-founder of Seattle Genetics. He is also the president and Chief Executive Officer of the company that was started several years ago. He also chairs the board of directors for Seattle Genetics. Mr. Siegall is a PhD holder, with a lot of experience in the biotechnology industry.
Mirna Therapeutics management is very excited about the new appointment. Dr. Siegall is expected to bring a lot of changes in the company since he has a lot of expertise in pharmaceutical world. He also boasts of his success in building a very successful oncology company. Mirna Therapeutics team with benefit from Dr. Siegall contributions, especially when developing microRNA therapeutics
MicroRNA therapeutics is actually a very exciting area of cancer research. According to Dr. Siegall, Mirna is one of the companies that is perfectly positioned with the right products. He was very excited to join the company to as part of the Board of Directors. The company had been involved in the miRNA field for some time, and he was looking forward to advance the promising programs that are needed by cancer patients.
Dr. Siegall co-founded a company known as Seattle Genetics in the year 1998. The company has done quite well under his leadership, and it has managed to build a wide range of antibody therapies that can address different medical needs of people suffering from cancer. The first commercial product from Seattle Genetics was known as ADCETRIS, and it was approved in the market in 2011.
Seattle Genetics is also believed to have entered into different strategic collaborations with some of the leading biotechnology and some pharmaceutical companies in the oncology department. All this while, Dr. Siegall has been in charge of raising the capital for the company. So far, he has managed to secure more than six hundred million dollars through private and public financings.